
Pharmacists reject tobacco giant's argument for more retail access to nicotine pouches
Imperial Tobacco's public relations campaign says that the ministerial order has made its Zonnic nicotine-replacement therapy pouches more difficult for smokers to access.
Pharmacists — 'front-line health professionals who are already time-squeezed and over-burdened' — are 'increasingly disgruntled by the new demands of this order,' it said.
SUBMITTED
An advertisement in a convenience store that sells Zonnic, a nicotine replacement product to help adults quit smoking that is not authorized to be sold to anyone under the age of 18.
Users place the pouches between their upper lip and gum for up to 60 minutes, releasing nicotine that temporarily curbs cravings and nicotine withdrawal symptoms, Imperial Tobacco says on its Zonnic website.
The association representing Manitoba pharmacists called that 'very, very strange.'
'There's no pharmacist being disgruntled or frustrated about the need to have people access these products in pharmacies,' said Britt Kural, pharmacy practice adviser with Pharmacists Manitoba.
'This is what we do — we do it really well.' She said pharmacists are among the most accessible health-care providers and able to help people find the right product to help them stop smoking.
'Pharmacists are experts in smoking cessation and we want to help people find the best options to help them in that journey,' Kural said Friday.
The pharmacy 'is exactly the right spot' for nicotine pouches that Imperial Tobacco and the government have classified as nicotine replacement therapy (NRT).
'We appreciate being able to have them available to consider for people when they want to stop smoking,' she said.
Not every pharmacist appreciates being 'the gatekeeper and policing an NRT product that has been approved by Health Canada,' said Imperial Tobacco's vice-president of corporate and regulatory affairs. Eric Gagnon said the company has heard concerns raised by pharmacy groups about it increasing their workload.
'I wouldn't say that everybody's on the same page,' he said from Montreal.
'The Neighbourhood Pharma Association has raised concern about moving (nicotine replacement therapies) behind the pharmacy counter,' said Gagnon. That could place an 'additional burden on pharmacy professionals,' he said.
'We hosted an event in Western Canada with pharmacists a few months ago, and they also raised some concerns.'
When the federal order was issued last August, Zonnic could no longer be sold where smokers regularly purchase cigarettes, and the flavours were restricted to mint and menthol. At the time, Gagnon accused the federal health minister of 'singling out' Imperial Tobacco, while giving pharmaceutical companies a pass.
'All smoking cessation products should be regulated in the same way,' Gagnon said in an Aug. 22, 2024 press release. 'This is not how good public health policy is made.'
When Zonnic tins — containing 24 pouches — were sold in convenience stores, there was an accelerated decline in cigarette sales, said Gagnon, adding that they've helped 'many thousands' quit smoking.
Nearly a year later, moving nicotine pouches behind the counter hasn't helped those trying to quit smoking, or Canada in meeting its stated goal of attaining a smoking rate of below five per cent by 2035, he said.
'We're concerned that either people will start smoking again or, as we have seen, people will start buying illegal nicotine products which often contain a lot more than the four milligrams that has been approved by Health Canada.'
He said specialty and online shops are illegally selling products that contain six, nine or even 15 milligrams of nicotine.
The push to get pouches sold over the counter alongside cigarettes comes after the settlement of a class-action lawsuit by provinces including Manitoba. Big Tobacco companies — including Imperial — are to cough up billions in after-tax profits solely from tobacco sales over the next 20 years.
'They need to get as many people addicted to alternative products — which includes pouches — as possible, for survival,' said the head of the Manitoba Tobacco Reduction Alliance. Cynthia Carr predicted after the tobacco settlement was announced in March that the companies would push for easier access to highly addictive nicotine pouches to grow their customer base.
'Not only are they handing over $6 billion or so, cash in hand, to start, they then have to start providing up to 85 per cent of their after-tax profits from tobacco. So if they only have a tiny portion left, of course they're going to sell every other product they can,' said Carr, a Winnipeg epidemiologist.
The federal government cracked down on the colourful packaging and flavours of nicotine pouches after studies showed youths were attracted and increasingly using them, Carr said Friday.
Wednesdays
What's next in arts, life and pop culture.
'The company was marketing this to that younger audience, making them fun, fancy flavours — cool designs that were really meant to appeal to a younger population,' said Kural.
'There can be some serious health consequences to underage individuals using these types of nicotine products or any nicotine product,' the pharmacist said. 'That younger population may not understand the consequences that nicotine can have on their overall health and especially in the growth stage of their health.'
Kural said she doesn't think that pharmacists — or any health-care practitioner — would support returning nicotine pouches to over-the-counter sales.
'We're trying to prevent this from falling into the hands of people who shouldn't be using it,' she said.
carol.sanders@freepress.mb.ca
Carol SandersLegislature reporter
Carol Sanders is a reporter at the Free Press legislature bureau. The former general assignment reporter and copy editor joined the paper in 1997. Read more about Carol.
Every piece of reporting Carol produces is reviewed by an editing team before it is posted online or published in print — part of the Free Press's tradition, since 1872, of producing reliable independent journalism. Read more about Free Press's history and mandate, and learn how our newsroom operates.
Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber.
Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

CTV News
7 hours ago
- CTV News
Canada likely to lose measles elimination status as outbreak continues: expert
Warning signage for suspected cases of measles is seen outside the main entrance of Woodstock General Hospital in Woodstock, Ont., Thursday, May 22, 2025. THE CANADIAN PRESS/Nicole Osborne Canada is at risk of losing its measles elimination status as an outbreak that started in New Brunswick last year continues to grow. Measles has been considered eliminated in Canada since 1998, and the country saw an average of 91 cases annually before October 2024, when the outbreak began. The designation means that, within a certain geographical region, there has been no sustained measles transmission over 12 consecutive months. Since then, of the 4,394 measles infections nationwide, Health Canada data shows that most individuals were exposed to the virus domestically (94 per cent) and were not vaccinated (88 per cent). So far, measles cases have been reported in every province and territory except Nunavut, Yukon, and Newfoundland and Labrador. According to most recent figures, Ontario has reported 2,353 cases as of July 29 and Alberta has reported 1,691 as of Aug. 5. One death was reported in Ontario in an infant who was born prematurely and had a congenital case of measles, as well as other underlying medical conditions. An April public health risk assessment conducted by Health Canada suggests that if the current chain of transmissions continues beyond October 2025, Canada could lose its elimination status. However, according to Janna Shapiro, a postdoctoral fellow at the University of Toronto's Centre for Vaccine Preventable Diseases, losing that designation looks likely. 'I think there's a pretty good chance, the way things are going now, that we will lose our measles elimination status,' she told CTV News Toronto in an interview. 'We really had our bulk of our cases in March or April', she said of Ontario, 'but that's not yet the case in Alberta. I think there's still quite a few new cases being reported on a weekly basis ' 'Whenever you see any type of infectious disease outbreak, there's an element of chance that the right people who are susceptible to being infected, happen to come in contact with that virus at a time that will allow it, or in a location or in a context, that allow it to spread,' she said. 'So yes, it is kind of freaky but that's how all infectious disease outbreaks start.' Michelle Knorr, a teacher from Saskatchewan, says her recent measles hospitalization has made her personally and professionally fearful of Canada's climbing cases. 'I think about the average 32 kids in a classroom in city schools. It would be a really dangerous thing to have a classroom of kids taken out by the measles. And most will manage it, most will be able to be resilient and overcome it, but some may not,' she warns. According to the Pan American Health Organization, Canada currently has more cases than any other country in the Americas.


Cision Canada
9 hours ago
- Cision Canada
Genome BC Funds Research into the Respiratory Fallout of Wildfires
VANCOUVER, BC, Aug. 6, 2025 /CNW/ - British Columbians know the stark realities of climate change, as wildfires surge across the province. Over a million hectares burned across BC in 2024, blanketing communities in thick smoke and dramatically increasing the number of hazy, lung-choking days. As summer becomes a season of smoke, this escalating environmental challenge also has a hidden, insidious impact: a profound and lasting toll on our respiratory health. Wildfire smoke is more than just an inconvenience; it's a dangerous cocktail of particulate matter that infiltrates our lungs and bodies, exacerbating existing conditions and potentially triggering new ones. The costs are staggering, both in human lives and healthcare dollars, with Health Canada estimating up to 240 deaths and $1.8 billion in annual costs due to short-term health effects alone. In response to this challenge, Genome BC is funding three research projects that will delve into the genetic-level impacts of wildfire smoke exposure. "These projects are specifically designed to uncover what makes our vulnerable populations – from newborns to those with chronic lung conditions – more susceptible to wildfire-related respiratory issues," said Suzanne Gill, Genome BC's President and CEO. "We hope this knowledge can both inform treatment and care within our healthcare system and reduce the overall economic toll of wildfires." PROJECT 1: Wildfire Exposure and Early Childhood Health The next generation of British Columbians could be feeling the effects of wildfires before they even take their first breath. This project uses a holistic approach to study the impact of disaster exposure during pregnancy, including if it can have lasting effects on how genes are expressed in developing children. This may increase the risk of respiratory diagnoses such as asthma, bronchitis, wheezing, hives, eczema and other allergic reactions. Lead Researcher, Dr. Michael Kobor of the University of British Columbia believes the results can inform public health policies about respiratory health, especially vulnerable groups such as infants and pregnant people. "With this research, we aim to better our understanding of the impacts of prenatal wildfire disaster exposure on the next generation," he said. "Early-life environments can have a lasting impact on people throughout the course of their lives, including on their health outcomes. We hope this work will help shape healthy futures for children as global temperatures rise and wildfires become increasingly common." PROJECT 2: How Wildfire Smoke Affects People with Chronic Obstructive Pulmonary Disease (COPD) For the over 2 million Canadians living with Chronic Obstructive Pulmonary Disease (COPD), wildfire smoke presents a particularly grave threat. COPD is already the leading cause of hospitalization in Canada, costing our healthcare system an estimated $1.5 billion annually. Wildfire smoke can significantly worsen symptoms and lead to severe complications for COPD patients. Dr. Graeme Koelwyn from Simon Fraser University and and Dr. Don Sin from the University of British Columbia are studying the genomic changes in innate immune cells — our first line of defense against inhaled particles — of COPD patients. Their research aims to understand how these immune cells respond to wildfire smoke in patients at the genetic level as symptoms become worse, and to identify effective treatments. "This information is critical to develop disease management and exposure mitigation strategies for people living with COPD," Dr. Koelwyn said, "especially in this time of increasing societal and financial burden within our changing world and environment." PROJECT 3: How Wildfire Smoke and Aeroallergens Affect Lung Health Dr. Emilia Lim and Dr. Min Hyung Ryu from the University of British Columbia are focusing on airborne allergens (aeroallergens) triggered by the increase of atmospheric carbon dioxide and high temperatures that happen when there are frequent wildfires. These situations also tend to prolong allergy seasons. Our bodies generate an immune response to protect us when aeroallergens enter our lungs. "Aeroallergens are harmful to everyone, but people with lung conditions such as asthma, COPD and lung cancer survivors are at higher risk," because their immune systems are theoretically less robust, Dr. Lim explains. "It's important to know how these groups are affected differently." The researchers want to understand the links between our individual genetic differences and environmental triggers. Dr. Ryu noted, "identifying populations that are susceptible to these changes can help us find better ways to prevent and treat respiratory diseases." The Value of Proactive Research The escalating financial burden of wildfire recovery underscores the urgent need for proactive strategies. These three projects exemplify how genomics research is providing critical insights into the complex interplay between our environment and our health. "With our proximity to wildfires and access to interdisciplinary teams, Canadian researchers are uniquely equipped to tackle these questions first-hand," said Gill. "The fundamental knowledge gained will lay the groundwork for better policy decisions and more efficient treatments in the future. Any breakthroughs in respiratory health or disease prevention will translate into economic benefits for British Columbians and beyond." About Genome British Columbia: Genome BC is a not-for-profit organization that has advanced genomics research and innovation for 25 years, growing a world-class life sciences sector in BC and delivering sustainable benefits for British Columbia, Canada and beyond. Genome BC has attracted over $1.1 billion in direct co-investment to the province, which has contributed to funding more than 600 genomics research and innovation projects. These initiatives enhance healthcare and address environmental and natural resource challenges, improving the lives of British Columbians. Genome BC also integrates genomics into society by supporting responsible research and innovation and fostering an understanding and appreciation of the life sciences among educators, students and the public.


Cision Canada
10 hours ago
- Cision Canada
Imfinzi approved in Canada as first and only perioperative immunotherapy for muscle invasive bladder cancer Français
MISSISSAUGA, ON, Aug. 6, 2025 /CNW/ - Health Canada has granted a Notice of Compliance (NOC) for Imfinzi ® (durvalumab) for the treatment of patients with resectable muscle invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by adjuvant Imfinzi monotherapy treatment after radical cystectomy. The approval is based on results from the NIAGARA Phase III trial, which were published in The New England Journal of Medicine. 1, 2 In a planned interim analysis, the Imfinzi-based perioperative regimen demonstrated a statistically significant and clinically meaningful 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus neoadjuvant chemotherapy with radical cystectomy alone (based on event-free survival [EFS] hazard ratio [HR] of 0.68; 95% confidence interval [CI] 0.56-0.82; p<0.0001). Estimated median EFS was not yet reached for the Imfinzi plus gemcitabine and cisplatin arm versus 46.1 months for the comparator arm. An estimated 67.8% of patients treated with the regimen were event free at two years compared to 59.8% in the comparator arm. 2 Results from the key secondary endpoint of overall survival (OS) showed that the Imfinzi-based perioperative regimen reduced the risk of death by 25% versus the comparator arm (based on OS HR of 0.75; 95% CI 0.59-0.93; p=0.011). Median survival was not yet reached for either arm. An estimated 82.2% of patients treated with the regimen were alive at two years compared to 75.2% in the comparator arm. 2 Imfinzi was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings. The most common adverse events (any Grade, occurring in ≥10% of patients) for the Imfinzi plus chemotherapy arm were nausea (53.6%), fatigue (51.5%), neutropenia (40.4%), anemia (38.7%), constipation (38.7%), decreased appetite (26.6%), rash (20.9%), pyrexia (20.8%), diarrhea (20.6%), abdominal pain (20.2%), vomiting (19.2%), blood creatine increased (18.5%), thrombocytopenia (17.2%), pruritus (15.1%), hypothyroidism (12.6%), neuropathy peripheral (12.5%), leukopenia (10.9%), and aspartate aminotransferase increased (10.4%). 1 "Health Canada's approval of this durvalumab-based perioperative regimen represents a major advance for Canadians with muscle invasive bladder cancer, where nearly half will relapse despite curative treatment," says Dr. Srikala Sridhar, Professor of Medicine at the University of Toronto, Genitourinary Medical Oncologist at the Princess Margaret Cancer Centre and NIAGARA trial investigator. "Findings from the NIAGARA trial showed that this new regimen reduces risk of recurrence and significantly improves survival – which may offer new hope and potential to transform care in this setting." "The high rate of recurrence associated with muscle invasive bladder cancer is an ongoing challenge and source of concern for physicians and patients," says Dr. Normand Blais, Medical Oncologist at the Centre hospitalier de l'Université de Montréal. "The Health Canada approval based on results from the NIAGARA trial may now offer us the opportunity to increase the chance of better patient outcomes and long-term survival by the use of immunotherapy in this setting, which is very good news for patients and their families." Bladder cancer is the 5th most common cancer in Canada, with more than 13,000 patients diagnosed each year. 3 The most common type of bladder cancer is urothelial carcinoma, which begins in the urothelial cells of the urinary tract. Bladder cancer is considered muscle invasive when there is evidence of the tumour invading the muscle wall of the bladder but no distant metastases. 4 In MIBC, approximately 50% of patients who undergo bladder removal surgery experience disease recurrence. 5 Treatment options that prevent disease recurrence after surgery are critically needed in this curative-intent setting. "This decision by Health Canada represents an important step forward for all Canadians affected by muscle invasive bladder cancer," says Michelle Colero, Executive Director, Bladder Cancer Canada. "For many patients and families, the fear of recurrence after surgery has been overwhelming. This new treatment option may offer renewed hope for longer, healthier lives." About NIAGARA 2 NIAGARA is a randomized, open-label, multi-centre, global Phase III trial evaluating perioperative Imfinzi as treatment for patients with MIBC before and after radical cystectomy. In the trial, 1,063 patients were randomized to receive four cycles of Imfinzi plus neoadjuvant chemotherapy prior to cystectomy followed by eight cycles of Imfinzi monotherapy, or neoadjuvant chemotherapy alone prior to cystectomy with no further treatment after surgery. NIAGARA is the largest global Phase III trial in this setting to date. The trial is being conducted at 192 centres in 22 countries across North America (including Canada), South America, Europe, Australia and Asia. Its dual primary endpoints are EFS and pathologic complete response at the time of cystectomy. Key secondary endpoints are OS and safety. About Imfinzi Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses. About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical business whose innovative medicines are used by millions of patients worldwide. The company's core areas of scientific focus are Oncology; Cardiovascular, Renal and Metabolic (CVRM); Rare Disease; Respiratory & Immunology; and Vaccine & Immune Therapies. In Canada, the company employs more than 2,400 people and recently announced a major expansion of its research footprint in Mississauga – including the expansion of its AstraZeneca R&D Hub and the creation of a new Alexion Development Hub for Rare Diseases. AstraZeneca was recently recognized as one of Canada's Top 100 Employers, one of Canada's Most Admired Corporate Cultures, and a Greater Toronto Top Employer. AstraZeneca is committed to contributing to a more sustainable future for people, society and planet taking important steps to help tackle some of the most pressing sustainability challenges globally – from climate and biodiversity loss, to health equity and health system resilience. AstraZeneca was one of the first seven companies globally to have its net zero targets verified by the Science-Based Targets initiative (SBTi) Corporate Net-Zero Standard. For more information, please visit the company's website at Imfinzi ® and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc. SOURCE AstraZeneca Canada Inc.